Evidence map›Paper›PMID 35615148›Full record

ArticleFrontiers in oncology2022

ROBO1 p.E280* Loses the Inhibitory Effects on the Proliferation and Angiogenesis of Wild-Type ROBO1 in Cholangiocarcinoma by Interrupting SLIT2 Signal.

Tao Zhou, Yaodong Zhang, Yananlan Chen, Jijun Shan, Jifei Wang, Yirui Wang, Jiang Chang, Wangjie Jiang, Ruixiang Chen, Ziyi Wang and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Tao ZhouHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yaodong ZhangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yananlan ChenHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jijun ShanHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jifei WangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yirui WangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jiang ChangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Wangjie JiangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ruixiang ChenHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ziyi WangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiaoli ShiHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yue YuHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Changxian LiHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiangcheng LiHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jiangsu Province Hospital · CNNanjing Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cholangiocarcinoma (CCA) remains one of the most lethal malignancies with an increasing incidence globally. Through whole-exome sequencing of 67 CCA tissues, we identified new mutated genes in CCA, including MACF1, METTL14, ROBO1, and so on. The study was designed to explore the effects and mechanism of ROBO1 wild type (ROBO1 Methods: Whole-exome sequencing was performed to identify novel mutations in CCAs. Results: Through whole-exome sequencing, we identified a novel CCA-related mutation, ROBO1 Conclusions: These results suggest that ROBO1 may act as a tumor suppressor and potential prognostic marker for CCA. ROBO1

Indexed as

angiogenesischolangiocarcinomanonsense mutationproliferationROBO1

Identifiers

PMID35615148
PMCPMC9124974
OpenAlexW4229370589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.